neuropeptide-y and Diabetic-Neuropathies

To study the impact on glucose handling of the observed hyperinsulinaemia and hypercorticism of the genetically obese fa/fa rats, simplified animal models were used. In the first model, normal rats were exposed to hyperinsulinaemia for 4 days and compared to saline-infused controls. At the end of this experimental period, the acute effect of insulin was assessed during euglycaemic-hyperinsulinaemic clamps. White adipose tissue lipogenic activity was much more insulin responsive in the "insulinized" than in the control groups. Conversely muscles from "insulinized" rats became insulin resistant. Such divergent consequences of prior "insulinization" on white adipose tissue and muscle were corroborated by similar divergent changes in glucose transporter (GLUT 4) mRNA and protein levels in these respective tissues. In the second model, normal rats were exposed to stress levels of corticosterone for 2 days. This resulted in an insulin resistance of all muscle types that was due to an increased glucose-fatty acid cycle, without measurable alteration of the GLUT 4 system. In genetically obese (fa/fa) rats, local cerebral glucose utilization was decreased compared to lean controls. This could be the reason for adaptive changes leading to increased levels in their hypothalamic neuropeptide Y levels and median eminence corticotropin-releasing-factor. Thus, in a third model, neuropeptide Y was administered intracerebroventricularly to normal rats for 7 days. This produced hyperinsulinaemia, hypercorticosteronaemia, as well as most of the metabolic changes observed in the genetically obese fa/fa rats, including muscle insulin resistance. These data together suggest that the aetiology of obesity-insulin resistance of genetically obese rodents has to be searched within the brain, not peripherally.

Topics: Animals; Awards and Prizes; Brain; Central Nervous System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Europe; Glucose; Glucose Transporter Type 4; History, 20th Century; Humans; Hyperinsulinism; Hypothalamus; Monosaccharide Transport Proteins; Muscle Proteins; Neuropeptide Y; Obesity; Peripheral Nervous System Diseases; Rats; Rats, Mutant Strains; Societies, Medical; Switzerland

Neuropeptides are ubiquitous in the sympathetic system and modulate transmission at the levels of the intermediolateral cell column, sympathetic ganglia, and neuroeffector junctions. Several neuropeptide-containing pathways from the hypothalamus and medulla modulate excitability of preganglionic neurons. Neuropeptides coexist with norepinephrine or acetylcholine in subpopulations of chemically coded, target-specific sympathetic ganglion neurons. Neuropeptide Y is colocalized in adrenergic vasoconstrictor neurons, whereas vasoactive intestinal polypeptide is colocalized in cholinergic sudomotor neurons. Neuropeptide expression is plastic; during development, neurons that switch from a noradrenergic to a cholinergic phenotype increase expression of vasoactive intestinal polypeptide, somatostatin, and substance P. Preganglionic inputs increase neuropeptide Y and inhibit substance P expression. Sympathetic denervation produces sprouting of sensory fibers containing substance P and calcitonin gene-related peptide in target tissues. Neuropeptides from preganglionic fibers (e.g., enkephalin) and primary afferents (e.g., substance P, vasoactive intestinal polypeptide) modulate transmission in sympathetic ganglia. Neuropeptide Y produces vasoconstriction, prejunctional inhibition of norepinephrine release, and postjunctional potentiation of norepinephrine effects. Plasma neuropeptide Y increases during intense sympathoexcitation, hypertension, and pheochromocytoma. Dystrophic neurites containing neuropeptide Y occur in human sympathetic ganglia during aging, diabetes, and dysautonomia. Sympathetic neuropeptides may thus have important clinical implications.

Topics: Aging; Animals; Autonomic Nervous System Diseases; Cats; Diabetic Neuropathies; Ganglia, Sympathetic; Humans; Hypothalamus; Medulla Oblongata; Neural Pathways; Neuronal Plasticity; Neuropeptide Y; Neuropeptides; Sympathetic Nervous System; Synaptic Transmission

We previously showed that peripheral neuropathy of the bone marrow was associated with loss of circadian rhythmicity of stem/progenitor cell release into the circulation. Bone marrow neuropathy results in dramatic changes in hematopoiesis that lead to microvascular complications, inflammation, and reduced endothelial repair. This series of events represents early pathogenesis before development of diabetic retinopathy. In this study we characterized early alterations within the bone marrow of streptozotocin (STZ)-induced diabetic rats following treatments that prevent experimental peripheral neuropathy. We asked whether bone marrow neuropathy and the associated bone marrow pathology were reversed with treatments that prevent peripheral neuropathy. Three strategies were tested: inhibition of neutral endopeptidase, inhibition of aldose reductase plus lipoic acid supplementation, and insulin therapy with antioxidants. All strategies prevented loss of nerve conduction velocity resulting from STZ-induced diabetes and corrected the STZ-induced diabetes-associated increase of immunoreactivity of neuropeptide Y, tyrosine hydroxylase, and somatostatin. The treatments also reduced concentrations of interleukin-1β, granulocyte colony-stimulating factor, and matrix metalloproteinase 2 in STZ-induced diabetic bone marrow supernatant and decreased the expression of NADPH oxidase 2, nitric oxide synthase 2, and nuclear factor-κB1 mRNA in bone marrow progenitor cells. These therapies represent novel approaches to attenuate the diabetic phenotype within the bone marrow and may constitute an important therapeutic strategy for diabetic microvascular complications.

Topics: Adipose Tissue; Animals; Bone Marrow; Cytokines; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Fish Oils; Gene Expression Regulation; Heterocyclic Compounds, 3-Ring; Hypoglycemic Agents; Imidazolidines; Inflammation; Insulin; Male; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Neuropeptide Y; Nitric Oxide Synthase Type II; Pain Measurement; Rats; Rats, Sprague-Dawley; RNA, Messenger; Somatostatin; Stem Cells; Streptozocin; Thioctic Acid; Tyrosine 3-Monooxygenase

Abnormal sensations such as pain and impairment of taste are symptoms of approximately 10% of patients having diabetes mellitus.. The aim of the study was to investigate and quantify the different neuropeptide containing nerve fibres in the vallate papilla of the diabetic rat.. Immunohistochemical methods were used to study the changes of the number of different neuropeptide containing nerve terminals located in the vallate papillae in diabetic rats. Diabetes was induced in the rats with streptozotocin.. Two weeks after streptozotocin treatment the number of the substance P, galanin, vasoactive intestinal polypeptide and neuropeptide Y immunoreactive nerve terminals was significantly increased (p<0.05) in the tunica mucosa of the tongue. The number of the lymphocytes and mast cells was also increased significantly. Some of the immunoreactive nerve terminals were located in the lingual epithelium both intragemmally and extragemmally and were seen to comprise dense bundles in the lamina propria just beneath the epithelium. No taste cells were immunoreactive for any of the investigated peptides. Vasoactive intestinal polypeptide and neuropeptide Y immunoreactive nerve fibres were not detected in the taste buds. For weeks after streptozotocin administration the number of the substance P, calcitonin gene related peptide and galanin immunoreactive nerve terminals was decreased both intragemmally and intergemmally. In case of immediate insulin treatment, the number of the immunoreactive nerve terminals was similar to that of the controls, however, insulin treatment given 1 week later to diabetic rats produced a decreased number of nerve fibers. Morphometry revealed no significant difference in papilla size between the control and diabetic groups, but there were fewer taste buds (per papilla).. Increased number of immunoreactive nerve terminals and mast cells 2 weeks after the development of diabetes was the consequence of neurogenic inflammation which might cause vasoconstriction and lesions of the oral mucosa. Taste impairment, which developed 4 weeks after streptozotocin treatment could be caused by neuropathic defects and degeneration or morphological changes in the taste buds and nerve fibres.

Topics: Animals; Calcitonin Gene-Related Peptide; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Galanin; Hypoglycemic Agents; Immunohistochemistry; Insulin; Lymphocyte Count; Male; Mast Cells; Nerve Endings; Neuropeptide Y; Rats; Rats, Inbred Strains; Streptozocin; Substance P; Taste Buds; Time Factors; Vasoactive Intestinal Peptide

Neuropeptide Y (NPY) is an important hormone in appetite regulation. Although the contribution of NPY to metabolic disease has been previously demonstrated, there are only a few reports addressing NPY plasma levels under distinct diabetic conditions. In this study we evaluated NPY plasma levels in diabetes mellitus type 2 (DM2) patients with (n=34) and without (n=34) diabetic polyneuropathy (PNP) and compared these with age and gender matched healthy controls (n=34). We also analyzed NPY plasma levels in gestational diabetes mellitus (GDM) patients with age and pregnancy-week matched controls with normal glucose tolerance (NGT). NPY concentration was determined using a commercially available radioimmunoassay kit. In addition, metabolic parameters of DM2 and GDM patients were recorded. One-way ANOVA tests with appropriate post hoc corrections showed elevated levels of NPY in DM2 patients with and without PNP when compared with those of healthy controls (122.32±40.86 and 117.33±29.92 vs. 84.65±52.17 pmol/L; p<0.001, p<0.005, respectively). No significant difference was observed between diabetic patients with and without PNP. The NPY levels were similar in the GDM group and in pregnant women with NGT (74.87±14.36 vs. 84.82±51.13 pmol/L, respectively). Notably, the NPY concentration correlated positively with insulin levels in DM2 patients (R=0.35, p<0.01). Our data suggest a potential involvement of circulating NPY in DM2 pathology.

Topics: Adult; Aged; Body Mass Index; Diabetes Mellitus, Type 2; Diabetes, Gestational; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Neuropeptide Y; Pregnancy; Radioimmunoassay

To observe the development of neuropathic changes in two types of experimental diabetes using changes in concentrations of NPY, CGRP and amines in the corpora cavernosa and seminal vesicles. Type I diabetes was studied in Wistar rats after 12 and 16 weeks of STZ-induced hyperglycaemia, and Type II diabetes was studied in prediabetic GK rats aged 52 weeks. Both were compared with age-matched normal Wistar rats.. NPY and CGRP were estimated using radioimmunoassay, and amines using HPLC.. There were significant changes in [CGRP] in the normal corpus cavernosum and in [NPY] in the normal seminal vesicle with age. STZ-diabetes, induced at 10 weeks of age, resulted in significant elevation of [NPY] and [CGRP] in the corpora cavernosa and seminal vesicles after 12 and 16 weeks of hyperglycaemia, relative to age-matched control rats. The GK rats were intolerant of glucose at 52 weeks of age, but did not have raised fasting blood glucose levels. [NPY], [CGRP] and [noradrenaline] in corpora cavernosa were significantly increased in the prediabetic GK animals relative to age-matched Wistar control rats. The seminal vesicles of GK rats showed a significant increase in [NPY], a non-significant increase in [CGRP], and a fall in [noradrenaline] relative to the age-matched Wistar controls.. The results indicate increased levels of NPY and noradrenaline in autonomic nerves, and of CGRP in sensory nerves, innervating the corpus cavernosum in Type I and in prediabetic Type II GK rats.

Topics: Aging; Animals; Blood Glucose; Calcitonin Gene-Related Peptide; Catecholamines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Erectile Dysfunction; Glucose Tolerance Test; Male; Neuropeptide Y; Penis; Prediabetic State; Rats; Rats, Mutant Strains; Rats, Wistar; Seminal Vesicles; Streptozocin; Sympathetic Fibers, Postganglionic

Topics: Adult; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Female; Heart Rate; Humans; Hypoglycemia; Insulin; Male; Neuropeptide Y; Pancreatic Polypeptide; Respiratory Mechanics

This study compared the effects of streptozotocin-induced diabetes in rats with those of two pro-oxidant interventions; a diet deficient in vitamin E and treatment with primaquine.. Measurements were made by the classic motor and sensory conduction velocity deficits and by indicators of the breakdown of small fibre phenotype i.e., sciatic nerve content of nerve growth factor and the neuropeptides, substance P and neuropeptide Y.. As with diabetes, the pro-oxidant interventions decreased conduction velocities (though the effect of vitamin E deficiency was not significant), the sciatic nerve content of nerve growth factor and the neuropeptides (all percentages refer to the mean value for the appropriate control groups). In diabetes, nerve growth factor was depleted to 50% in the control rats (p < 0.05); oxidative stress depleted nerve growth factor to 64% (primaquine; p < 0.05) and 81% (vitamin E deficient; not significant) of controls. Substance P was depleted to 51% in the control rats (p < 0.01) with depletions to 74% and 72% (both p < 0.01) by oxidative stress; equivalent depletions for neuropeptide Y were 38% controls in diabetes (p < 0.001) and 67% (primaquine; p < 0.001) and 74% (vitamin E deficient; p < 0.05) for oxidative stress.. The relative magnitudes of these changes suggest an effect in diabetes of oxidative stress, coupled with some other cellular event(s). This is supported by the effects of a diester of gamma-linolenic acid and alpha-lipoic acid, which completely prevented the effects on the pro-oxidant interventions on conduction velocity, nerve growth factor and neuropeptide contents, but was only partially preventative in diabetes.

Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; gamma-Linolenic Acid; Male; Nerve Growth Factor; Neural Conduction; Neurons; Neuropeptide Y; Oxidative Stress; Phenotype; Primaquine; Rats; Rats, Wistar; Sciatic Nerve; Substance P; Thioctic Acid; Vitamin E

Neuropeptide Y (NPY) is a potent vasoconstrictor peptide that is abundant in the brain and the peripheral sympathetic nervous system. In the present study we investigated possible changes in plasma immunoreactive (IR)-NPY concentrations and urinary IR-NPY excretion in patients with non-insulin dependent diabetes mellitus (NIDDM) and the relationship to diabetic complications, such as nephropathy and neuropathy. IR-NPY in plasma and urine was measured by radioimmunoassay in 69 patients with NIDDM. Plasma IR-NPY concentrations in patients with advanced nephropathy (creatinine clearance <30 ml/min) (100.5 +/- 10.3 pmol/l, n=9, mean +/- SEM) were higher than in the control subjects (55.0 +/- 6.8 pmol/l, n=15) (P<0.02). Urinary excretion of IR-NPY and fractional excretion of NPY were also increased in the patients with advanced nephropathy. Sephadex G-50 column chromatography of the urine extracts obtained from healthy subjects, diabetic patients with renal failure and non-diabetic patients with renal failure showed an immunoreactive peak eluting in the NPY position. On the other hand, neither plasma nor urinary IR-NPY was high in patients with retinopathy, or in patients with peripheral neuropathy. The present study has, for the first time, shown high plasma IR-NPY concentrations and urinary IR-NPY excretion in NIDDM patients with advanced nephropathy.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Female; Glycated Hemoglobin; Humans; Male; Middle Aged; Neuropeptide Y; Reference Values

Untreated streptozotocin-diabetic (7 weeks duration) rats showed reductions (all p < 0.01; percentages in brackets) in motor and sensory nerve conduction velocity (MNCV; 14%, SNCV; 17%) and in sciatic nerve contents of nerve growth factor (NGF; 57%), substance P (SP; 53%) and neuropeptide Y (NPY; 39%). Treatment with a gamma-linolenic acid-alpha-lipoic acid conjugate (GLA-LA; 35 mg x day(-1) x rat(-1)) attenuated (p < 0.05) these reductions to MNCV (8%), SNCV (5%), NGF (19%), SP (23%), NPY (20%), such that the values in GLA-LA-treated diabetic rats did not differ significantly from those of control non-diabetic animals. Treatment with alpha-lipoic acid alone at 100 mg/kg i.p. was without effect on these variables except for NGF (33% reduction, p < 0.05) and treatment with the antioxidant, butylated hydroxytoluene (1.5% dietary supplement) did not affect any deficits. These data show that GLA-LA is effective in improving both electrophysiological and neurochemical correlates of experimental diabetic neuropathy.

Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Diabetes Mellitus, Experimental; Diabetic Neuropathies; gamma-Linolenic Acid; Male; Motor Neurons; Nerve Growth Factors; Neural Conduction; Neurons, Afferent; Neuropeptide Y; Rats; Rats, Wistar; Sciatic Nerve; Substance P; Thioctic Acid

Neuropeptide Y is a regulatory peptide found in adrenergic and non-adrenergic neurons. Diabetes, which may cause autonomic neuropathy, induces an increase in hypothalamic neuropeptide Y (NPY) levels; thereby we measured the effects of chronic diabetes on neuropeptide Y in the intestine. Rats were injected with streptozotocin (65 mg/kg) and maintained for up to 20 weeks. Another group of rats was injected with 6-hydroxydopamine (50 mg/kg) x 2 to induce sympathectomy. Ileum and colon were harvested and both whole and microdissected intestine were (1) stained with antibodies to neuropeptide Y, vasoactive intestine polypeptide, and neurofilaments or (2) extracted for neuropeptide Y radioimmunoassay. Neuropeptide Y levels were similar under all conditions in the colon, but there was a trend toward an increase in the diabetic whole ileum. NPY levels were significantly increased in the dissected myenteric plexus ileal layer in diabetics. We noted an increase in the number of neuropeptide Y and vasoactive intestine polypeptide immunoreactive myenteric neurons in diabetics and after 6-hydroxydopamine-induced sympathectomy. Diabetes, and to a lesser extent sympathectomy, induced an increase in ileal neuropeptide Y levels and neuropeptide Y-staining myenteric but not submucosal neurons. Altered tissue levels of neuropeptide Y may account for certain of the gastrointestinal disturbances commonly seen in diabetes.

Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Immunohistochemistry; Intestinal Mucosa; Intestines; Myenteric Plexus; Neurofilament Proteins; Neurons; Neuropeptide Y; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Staining and Labeling; Vasoactive Intestinal Peptide

The effect of acrylamide intoxication (a widely used model for autonomic neuropathy) on the fluorescence intensity and density of catecholamine- and peptide-containing nerve fibres and tissue content of noradrenaline and the peptides vasoactive intestinal polypeptide, calcitonin gene-related peptide, substance P and neuropeptide Y in the enteric nerves of rat ileum was examined. Histochemical and immunohistochemical techniques were used to localize catecholamine- and peptide-containing nerve fibres. The tissue content of noradrenaline was measured using high-performance liquid chromatography, and an enzyme-linked immunosorbent assay technique was used to determine the tissue content of the peptides investigated. Acrylamide intoxication caused a significant decrease in the density of catecholamine-containing nerve fibres and tissue content of noradrenaline in the myenteric plexus of rat ileum. A decrease in tissue content and immunoreactivity of calcitonin gene-related peptide and an increase in vasoactive intestinal polypeptide was seen in the myenteric plexus of ileum from acrylamide-intoxicated rats. In the submucous plexus, the acrylamide treatment caused a decrease in calcitonin gene-related peptide immunoreactivity and an increase in vasoactive intestinal polypeptide and neuropeptide Y immunoreactivity. There was no change in either tissue content or immunoreactivity of substance P in both myenteric and submucous plexuses of the treated rat ileum. These changes have a striking similarity with those found in the enteric nerves of streptozotocin-diabetic rat ileum, suggesting the possible presence of an underlying common mechanism(s) in the development of neuropathic changes in the autonomic nerves of acrylamide-intoxicated and streptozotocin-diabetic rats.

Topics: Acrylamide; Acrylamides; Animals; Autonomic Pathways; Calcitonin Gene-Related Peptide; Catecholamines; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Intestines; Male; Nerve Fibers; Neuropeptide Y; Norepinephrine; Rats; Rats, Wistar; Substance P; Vasoactive Intestinal Peptide

Complications of diabetes include sensory and autonomic neuropathy. The aim of the present paper was to study the degree of sensory and autonomic neuropathy and correlate these findings with the distribution and density of neuropeptidergic nerve fibers in the skin of the forearm of diabetic patients and healthy controls. We investigated 30 diabetics (24 type 1 and 6 type 2) and compared them with 13 healthy controls. There were no differences between the groups with respect to density and distribution of nerve fibers displaying immunoreactivity to the pan-neuronal marker PGP 9.5 and sensory and parasympathetic neuropeptides (substance P, calcitonin gene-related peptide and vasoactive intestinal peptide). By contrast, nerve fibers containing neuropeptide Y, a marker of sympathetic neurons, were reduced in number in the diabetic patients. C-fiber function (measured as the axon-reflex-evoked flare response) became impaired with increasing age in all subjects. The diabetic patients, however, showed a reduced flare compared to age-matched healthy controls. The reduction was particularly prominent in the younger patients (20-50 years). There was a greater reduction of the flare in neuropathic patients than in non-neuropathic patients, but there was no correlation between the degree of functional impairment and the duration of the disease.

Topics: Adult; Aged; Autonomic Nervous System; Axons; Calcitonin Gene-Related Peptide; Case-Control Studies; Diabetes Mellitus; Diabetic Neuropathies; Female; Forearm; Humans; Male; Middle Aged; Nerve Fibers; Neurons, Afferent; Neuropeptide Y; Parasympathetic Nervous System; Skin; Substance P; Sympathetic Nervous System; Thiolester Hydrolases; Ubiquitin Thiolesterase; Vasoactive Intestinal Peptide

To clarify the impact of autonomic neuropathy in diabetic patients, we have conducted a prospective study of 58 Type 1 and 51 Type 2 diabetic patients (investigated at baseline, after 4, and after 7 years). In Type 1 diabetic patients, the sympathetic nerve function (orthostatic acceleration and brake indices) and in Type 2 patients, parasympathetic nerve function (R-R interval variation; E/l ratio) deteriorated during 7 years of prospective observation. Symptoms of autonomic neuropathy were associated with signs of autonomic neuropathy (low brake indices) in Type 1 but not in Type 2 diabetic patients. In the latest assessment 24 h ECG recording was performed and blood samples assayed for neuropeptide Y (NPY) and motilin were obtained. Type 1 diabetic patients with parasympathetic neuropathy (abnormal E/l ratio) showed significantly lower SD value (less variation in the R-R intervals; 29 [17] vs 50 [16], [mean (interquartile range)]; p = 0.001) and higher postprandial plasma motilin values (70 [20] pmol l-1 vs 50 [15] pmol l-1; p < 0.01) than patients with normal parasympathetic nerve function. In Type 2 diabetic patients, sympathetic neuropathy (low brake indices) was associated with an increased frequency of ventricular extra systolic beats during 24 h ECG recording (rs = 0.65; p < 0.01). Postprandial plasma NPY levels were not associated with disturbed autonomic nerve function.

Topics: Adolescent; Adult; Autonomic Pathways; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Motilin; Neuropeptide Y; Prospective Studies

The effect of diabetes on the density of peptide-containing nerves in the pyloric sphincter of streptozotocin-induced diabetic rats and the possible preventive action of the ganglioside mixture AGF1 on the diabetes-induced changes were investigated.. Immunohistochemical techniques were used to localize the general neuronal marker protein gene product 9.5 and the neuropeptides, calcitonin gene-related peptide, [met]-enkephalin, neuropeptide Y, substance P, and vasoactive intestinal polypeptide.. The density of neurones showing immunoreactivity to the above peptides in nerves supplying the thickened circular muscle layer of the pyloric sphincter was reduced extensively in diabetic rats. In the ganglioside-treated diabetic animals, this reduction was prevented; indeed, calcitonin gene-related peptide- and substance P-like immunoreactivity in the ganglioside-treated diabetic rats exceeded that seen in control animals. In the ganglioside-treated controls, there was no significant difference in the peptide immunoreactivity from that of untreated controls.. The results of the present study show that the ganglioside mixture AGF1 is effective in protecting the nerves of the pyloric sphincter from diabetes-induced changes.

Topics: Animals; Biomarkers; Calcitonin Gene-Related Peptide; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enkephalin, Methionine; Fluorescent Antibody Technique; Gangliosides; Male; Neurons; Neuropeptide Y; Pylorus; Rats; Rats, Wistar; Substance P; Thiolester Hydrolases; Ubiquitin Thiolesterase; Vasoactive Intestinal Peptide

Plasma neuropeptide Y (NPY), plasma galanin and plasma catecholamines were determined before and during an ergometer exercise test in 11 type 1 diabetic patients (age 19-36 years, mean 30; duration of diabetes 2-18 years, mean 9) with autonomic dysfunction and in 13 age-matched healthy controls (age 24-36 years, mean 29). Before exercise, plasma NPY (100 +/- 6 pmol/l vs 144 +/- 7 pmol/l; P less than 0.001) and plasma galanin (54 +/- 3 pmol/l vs 77 +/- 5 pmol/l; P less than 0.005) were significantly lower in patients than in controls. During exercise, plasma NPY, plasma adrenaline, and plasma noradrenaline increased in patients and controls while galanin only increased in patients. Since there was a direct correlation between plasma NPY before exercise and the increment (delta 80%) in noradrenaline during exercise (r = 0.54; P less than 0.01), it is suggested that plasma NPY determined in the basal situation may be a useful marker of sympathetic nerve failure in diabetic patients.

Topics: Adult; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Epinephrine; Female; Galanin; Humans; Male; Neuropeptide Y; Norepinephrine; Peptides; Physical Exertion; Reference Values

We have previously shown depletion of nerves and neuropeptides in skin biopsies of diabetic patients, even in the absence of clinical signs and symptoms of sensory and autonomic neuropathy, but were unable to examine the changes occurring at an early stage of the disease. Therefore, the distribution and relative density of peptide-containing nerves was studied in streptozotocin-treated rats in order to assess the progression of neural changes in the initial stages of diabetes. Skin samples dissected from the lip and footpad of diabetic rats, 2, 4, 8 and 12 weeks after streptozotocin injection and age matched controls were sectioned and were immunostained with antisera to the neuropeptides substance P, calcitonin gene-related peptide (CGRP), vasoactive intestinal polypeptide (VIP) and neuropeptide Y (NPY), and to a general neural marker, protein gene product 9.5 (PGP 9.5). No change was apparent in the distribution or relative density of immunoreactive cutaneous nerve fibres 2, 4 and 8 weeks after streptozotocin treatment. By 12 weeks there was a marked increase in the number of CGRP-immunoreactive fibres present in epidermis and dermis, and of VIP-immunoreactive fibres around sweat glands and blood vessels. A parallel increase was seen in nerves displaying PGP 9.5 immunoreactivity. No differences were detected in nerves immunoreactive for either substance P in the epidermis and dermis, and NPY around blood vessels. The alterations in the peptide immunoreactivities may be similar in the initial stages of human diabetes.

Topics: Animals; Calcitonin Gene-Related Peptide; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Fluorescent Antibody Technique; Male; Nerve Fibers; Neuropeptide Y; Neuropeptides; Rats; Rats, Inbred Strains; Skin; Substance P; Ubiquitin Thiolesterase; Vasoactive Intestinal Peptide

Immunocytochemistry for the general neuronal marker protein gene product 9.5 and four neuropeptides (calcitonin gene-related peptide, substance P, vasoactive intestinal polypeptide and neuropeptide Y) was performed on 20 skin biopsy specimens from 19 diabetic patients, age range 20-75 years, 17 Type 2 (non-insulin-dependent) and 3 Type 1 (insulin-dependent). Fifteen specimens were from the lower limb, 3 from the upper limb and 2 from the abdominal wall. Seven subjects had lower limb neurophysiological tests. All but one specimen showed reduced protein gene product 9.5 and neuropeptide immunoreactivity. Reduced protein gene product 9.5 and neuropeptide immunoreactivity was found in specimens taken from the abdominal wall and hand as well as those from the leg, and also in specimens from patients undergoing amputation for peripheral vascular disease. In general, the greater the number of abnormal neurophysiological tests, the greater the extent of neuronal abnormalities. Three patients with normal tests had abnormalities of dermal innervation. While these changes are also found in other axonal neuropathies, in the absence of other causes of peripheral nerve disease and of macrovascular disease, immunocytochemistry of skin biopsies may have a role in the assessment of diabetic neuropathy and its response to treatment.

Topics: Adult; Aged; Biopsy; Calcitonin Gene-Related Peptide; Diabetes Mellitus; Diabetic Neuropathies; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neuropeptide Y; Neuropeptides; Skin; Substance P; Ubiquitin Thiolesterase; Vasoactive Intestinal Peptide

The distribution of adrenergic and vasoactive intestinal polypeptide-, neuropeptide Y- and substance P-immunoreactive nerves was studied histochemically and immunohistochemically in the irides of rats 8 weeks after the induction of diabetes with streptozotocin. In the control animals, catecholamine-containing, vasoactive intestinal polypeptide- and substance P-immunoreactive nerve fibres were found in the constrictor pupillae, dilator muscle and the ciliary processes. They also formed perivascular nerve plexuses of blood vessels in the dilator muscle. Neuropeptide Y-immunoreactive nerve fibres were only observed in the dilator muscle and ciliary processes. In the irides from diabetic animals, a considerable increase was observed in the fluorescence intensity and/or density of vasoactive intestinal polypeptide-immunoreactive nerves. Some varicosities of the vasoactive intestinal polypeptide-immunoreactive nerves appeared enlarged. In contrast, no apparent change in the density and/or fluorescence intensity of catecholamine-containing, neuropeptide Y- and substance P-immunoreactive nerve fibres was observed in the irides from diabetic animals when compared with controls. The results are discussed in relation to the symptoms of autonomic neuropathy of the irides in diabetes.

Topics: Adrenergic Fibers; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Iris; Male; Nerve Fibers; Neuropeptide Y; Rats; Rats, Inbred Strains; Substance P; Vasoactive Intestinal Peptide

The autonomic innervation of the seminal vesicle from 8 and 16 week streptozotocin-induced diabetic rats and age-matched controls was studied by pharmacological, histochemical and immunohistochemical methods. Contractions in response to electrical field stimulation, which were abolished using prazosin (2 microM) or tetrodotoxin (one to 1.6 microM), and to noradrenaline were significantly increased in both eight and 16 week diabetic animals. The contractile response to acetylcholine was significantly increased in the 16 week diabetic rats only, when compared with controls. Although these responses were significantly increased, no difference was found in ED50 and EF50 values between control and diabetic rats. Vasoactive intestinal polypeptide (0.3 microM) had no effect on resting tension or nerve-mediated responses. In seminal vesicles from control animals, both vasoactive intestinal polypeptide-immunoreactive and acetylcholinesterase-containing nerves were localised around the folds of the columnar epithelium of secretory cells, in contrast to neuropeptide Y-immunoreactive and catecholamine-containing nerves which were found in the smooth muscle layers. In seminal vesicles from both eight and 16 week diabetic animals no difference was seen in distribution or density of acetylcholinesterase-containing nerves; there was an increase in density and fluorescence intensity of vasoactive intestinal polypeptide- and neuropeptide Y-immunoreactive nerves and a decrease in catecholamine-containing nerves compared with controls. The results are discussed in relation to autonomic neuropathy in diabetes.

Topics: Acetylcholine; Adrenergic Fibers; Animals; Cholinergic Fibers; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relationship, Drug; Electric Stimulation; Histocytochemistry; Immunohistochemistry; Male; Neuropeptide Y; Norepinephrine; Peptides; Prazosin; Rats; Seminal Vesicles; Tetrodotoxin; Time Factors; Vasoactive Intestinal Peptide